Abstract:Objective To compare quantitative proteomic analysis of bromotetrandrine (W198) which was a Class I new antitumor drug in China and tetrandrine (Tet) in K562 cell line using O-18-labeling method. Methods To illustrate its mechanism, a shotgun quantitative proteomic strategy employing 2D LC-MS-MS and trypsin catalyzed O-18-labeling quantification was carried out in this study. Compared to normal chronic leukemia cell line K562 and K562 induced by Tet, the proteomic changes of K562 induced by W198 were investigated. In order to validate the quantitation by the O-18-labeling, the analysis was done on an equivalent sample composed of the same amount of labeled and unlabeled proteins from normally cultured cells to act as a reference to the comparative sample. Results A threshold of +/- 2-fold change for deciding whether a protein concentration was changed was settled for the following experiments. Comparing the 105 identified soluble proteins' expression levels of the apoptosis starting up K562 cells after W198 induction with the normally cultured cells, 16 proteins were found with significantly altered expression levels after W198 treatment. Eight proteins were up-expressed including HMGB2, peroxiredoxin-2, and eIF4A-I, etc. Eight proteins were down-expressed including TCP-1, GRP94, GST-pi, and SFGHs, etc. Compared to K562 induced by Tet, eight proteins of K562 were found with significantly altered expression levels after W198 treatment. Five proteins were up-expressed including HSP 90-beta and 40S ribosomal protein S15a, etc. Three proteins were down-expressed including phosphoglycerate kinase 1, isoform 5 of interleukin enhancer-binding factor 3, etc. Conclusion The O-18-labeling MS-MS-based method is ideal as a discovery tool, but it is not suitable for validation using a large number of samples. Other more effective methods, such as Western blotting should be used for further validation of candidate cancer proteins discovered from O-18-labeling samples. In total, 105 soluble proteins were discovered, and 16 proteins were found with significantly altered expression levels after W198 treatment. These repressed or activated proteins are the potential drug targets of W198, which may provide novel targets for future development of biomarkers for cancer therapy.

Proteomic Analysis for Malonylastragaloside I in U937 Leukemia Cells by Modified Label-free Quantitative Strategy with LC Chip Q-TOF MS/MS

Comparative evaluation of label-free quantification strategies.

Quantitative Analysis of Global Proteome and Lysine Acetylome Reveal the Differential Impacts of VPA and SAHA on HL60 Cells

Analysis of Comparative Proteomic and Potent Targets of Peniciketal A in Human Acute Monocytic Leukemia.

Quantitative Profiling of Post-translational Modifications by Immunoaffinity Enrichment and LC-MS/MS in Cancer Serum without Immunodepletion

Quantitative Proteomic Analysis of Bromotetrandrine and Tetrandrine in K562 Cell Line Using 18O-Labeling Method

Analysis of the Different Proteomes Between the Acute Leukemia Cells and Normal White Blood Cells

[Preliminarily Screening of Serum Characteristic Markers in Acute Myeloid Leukemia and Clinical Significance].

Determination of differentially regulated proteins upon proteasome inhibition in AML cell lines by the combination of large-scale and targeted quantitative proteomics

Proteomics Analysis of Human Renal Clear Cell Carcinoma by Two MS2-based Label-free Approaches

Large-scale quantitative proteomic study of PUMA-induced apoptosis using two-dimensional liquid chromatography-mass spectrometry coupled with amino acid-coded mass tagging.

Screening for methylation-silenced genes in acute myeloid leukemia HL-60 cell line by a quantitative proteomic approach

Quantitative Approach for Protein Analysis in Small Cell Ensembles by an Integrated Microfluidic Chip with MALDI Mass Spectrometry

Quantitative Proteomic Analysis and Comparison of Two Bone Marrow Stromal Cell Lines Using the SILAC Method.

Nano-ESI-MS/MS Identification on Differentiation-associated Proteins in M1 Mouse Myeloid Leukemia Cells Induced by IL-6

Comprehensive Quali-Quantitative Profiling of Neutral and Sialylated O-glycome by Mass Spectrometry Based on Oligosaccharide Metabolic Engineering and Isotopic Labeling

Proteomic Analysis on Multi-Drug Resistant Cells Hl-60/Dox of Acute Myeloblastic Leukemia

Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling

A Systematic N-terminal Peptide Quantitative Labeling Strategy for Differential Proteomic Analysis.

Analysis of Different Proteome of Acute Leukemia Cells Derived from Granulocytic Lineage and Monocytic Lineage

Application of the Silac (stable Isotope Labelling with Amino Acids in Cell Culture) Technique in Quantitative Comparisons for Tissue Proteome Expression